Guidelines for Systemic Treatment of Patients With Psoriasis at the University Clinic for Dermatology – Skopje
Year: 2025
Type: article
Abstract: Psoriasis is a chronic autoimmune disease that causes inflammation in your skin and encompasses several disease subtypes (plaque, inverse, guttate, pustular, erythrodermic, nail and sebopsoriasis), requiring a standardized approach to diagnosis and treatment. According to current recommendations, the treatment involves the use immunosuppressants and biologic therapy which has already been approved as a first-line treatment for moderate to severe psoriasis in Europe and USA. These guidelines are made for the needs of the University Clinic for Dermatology – Skopje and are based on the European guidelines on the systemic treatment of psoriasis (EuroGuiDerm Guidelines on the systemic treatment of Psoriasis vulgaris, 2020). They include a system for grading disease severity, and recommendations for treatment and monitoring. Systemic treatment modalities included in these guidelines are: acitretin, ciclosporin, methotrexate, adalimumab, apremilast, brodalumab, certolizumab, pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, secukinumab, tildrakizumab and ustekinumab.
Source: Academic Medical Journal
DOI: 10.53582/amj255101s
Institution: Ss. Cyril and Methodius University in Skopje
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: diamond
OpenAlex ID: W4411577675